279. Huge venous malformation with cervical, oral and pharyngeal diffuse lesion Clinical trials / Disease details
Clinical trials : 14 / Drugs : 24 - (DrugBank : 9) / Drug target genes : 3 - Drug target pathways : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04258046 (ClinicalTrials.gov) | March 31, 2020 | 16/1/2020 | Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation | Phase II Clinical Trial of MEK Inhibitor Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation (VM) | Venous Malformation;Arterial Disease | Drug: Trametinib tablet | Stanford University | Boston Children's Hospital | Not yet recruiting | 12 Years | 60 Years | All | 30 | Phase 2 | United States |